Please login to the form below

Not currently logged in
Email:
Password:

Industry welcomes European diagnostics regulations

Trade bodies say they will support greater use of personalised medicines
Companion diagnostics

Industry bodies have welcomed new European medical device legislation, which they say will support greater use of companion diagnostics and personalised medicines.

The Regulation on In-Vitro Diagnostic (IVD) Medical Devices was agreed by the European Council and Parliament alongside wider med device reforms, brought in in the wake the PIP breast implant scandal.

The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) voiced qualified support for the new IVD regulations.

Though described as a “compromise agreement”, the trade bodies gave their approval in a joint statement, saying medical devices are “essential for the safe and effective use of a corresponding medicinal product”.

Barbara Freischem, executive director of EBE, commented: “I am pleased that the council and the Parliament Health Committee have finally reached an agreement under the strong leadership of MEP Peter Liese.

“The legislation will provide a firm basis for a rapid expansion in companion diagnostics and personalised medicine, which offers huge potential for patients and public health.”

However, the two trade bodies anticipate the added safety checks will be “challenging to implement for IVD manufacturers”.

In addition to increased emphasis on follow-up quality, performance and safety of marketed devices, the new rules also require consultation with national or European regulators on a device's suitability in relation to the drug prior to any license application.

EFPIA and the EBE also have expressed concern over the lack of guidance for the process, and called on the European Parliament Health Committee to provide clear direction for how a companion device's “scientific validity” will be evaluated.

Additionally, the EBE and EFPIA identified Next Generation Sequencing (NGS) tests - used to screen patients for biomarkers - as another area in which further detail on how the new legislation will regulate such tests is required.

Freischam added: “Clarifications are still needed on a number of topics and the biopharmaceutical industry will remain actively engaged to ensure that the regulation reaches its goal for the benefit of patients.”

Article by
Dominic Tyer

21st June 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics